Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology.</li><li> 2Q financials show the company has solid cash and is attracting interest from potential partners.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology. 2Q financials show the company has solid cash and is attracting interest from potential partners.

EVAX:  Dual-income, AI-Biotech Company Attracting Interest

<ul><li>EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.</li><li>The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology.</li><li> The company aims to be cash-flow neutral in 2024 and continues to develop relationships with major pharmaceutical companies, while also pushing treatments through the FDA approval process.</li></ul>

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed treatments.The company has two streams of possible revenue: from the treatments themselves and from the licensing of the AI technology. The company aims to be cash-flow neutral in 2024 and continues to develop relationships with major pharmaceutical companies, while also pushing treatments through the FDA approval process.

EVAX:  Initiating Coverage: Using AI for Better Health Outcomes

Denmark

Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Evaxion Biotech A/S (EVAX US)

EVAX: Dual-income, AI-Biotech Company Attracting Interest

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

EVAX: Initiating Coverage: Using AI for Better Health Outcomes

EVAX is a clinical stage company that has proprietary AI models designed to more efficiently and more accurately target much-needed...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)